Exelixis Inc EXEL
News
Exelixis Presents Final Overall Survival Results from Phase 3 CONTACT-02 Pivotal Study Evaluating Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Metastatic Castration-Resistant Prostate Cancer at ESMO 2024
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in September
Exelixis Announces Second Quarter 2024 Financial Results and Provides Corporate Update
Exelixis Announces U.S. Food and Drug Administration (FDA) Accepted the Supplemental New Drug Application for Cabozantinib for Patients with Advanced Neuroendocrine Tumors
Exelixis to Release Second Quarter 2024 Financial Results on Tuesday, August 6, 2024
Exelixis Files Patent Complaint Against Cipla's Cancer Treatment
Exelixis to license Insilico AI-designed cancer drug